Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.10
HOLX's Cash to Debt is ranked lower than
55% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. HOLX: 0.10 )
HOLX' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.1

Equity to Asset 0.23
HOLX's Equity to Asset is ranked lower than
54% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. HOLX: 0.23 )
HOLX' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.88
Current: 0.23

0.22
0.88
F-Score: 4
Z-Score: -0.27
M-Score: -3.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -36.36
HOLX's Operating margin (%) is ranked higher than
52% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. HOLX: -36.36 )
HOLX' s 10-Year Operating margin (%) Range
Min: -123.18   Max: 20.99
Current: -36.36

-123.18
20.99
Net-margin (%) -47.06
HOLX's Net-margin (%) is ranked higher than
51% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.56 vs. HOLX: -47.06 )
HOLX' s 10-Year Net-margin (%) Range
Min: -135.4   Max: 16.59
Current: -47.06

-135.4
16.59
ROE (%) -60.41
HOLX's ROE (%) is ranked higher than
50% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. HOLX: -60.41 )
HOLX' s 10-Year ROE (%) Range
Min: -81.32   Max: 13.96
Current: -60.41

-81.32
13.96
ROA (%) -13.03
HOLX's ROA (%) is ranked higher than
57% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. HOLX: -13.03 )
HOLX' s 10-Year ROA (%) Range
Min: -39   Max: 12.23
Current: -13.03

-39
12.23
ROC (Joel Greenblatt) (%) -117.92
HOLX's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. HOLX: -117.92 )
HOLX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -393.19   Max: 104.07
Current: -117.92

-393.19
104.07
Revenue Growth (%) 12.70
HOLX's Revenue Growth (%) is ranked higher than
86% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. HOLX: 12.70 )
HOLX' s 10-Year Revenue Growth (%) Range
Min: -7.7   Max: 35.9
Current: 12.7

-7.7
35.9
EPS Growth (%) 162.90
HOLX's EPS Growth (%) is ranked higher than
99% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. HOLX: 162.90 )
HOLX' s 10-Year EPS Growth (%) Range
Min: -68.1   Max: 369.3
Current: 162.9

-68.1
369.3
» HOLX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HOLX Guru Trades in Q1 2013

Pioneer Investments 1,475,200 sh (+334.39%)
RS Investment Management 508,600 sh (+47.61%)
Ken Fisher 133,100 sh (+21.22%)
Irving Kahn 1,562,574 sh (+2.41%)
Prem Watsa 20,000 sh (unchged)
Jean-Marie Eveillard 15,000 sh (unchged)
Mariko Gordon 15,063 sh (unchged)
Steven Cohen Sold Out
Jim Simons 1,155,518 sh (-46.88%)
» More
Q2 2013

HOLX Guru Trades in Q2 2013

Ray Dalio 43,800 sh (New)
Steven Cohen 744,380 sh (New)
Vanguard Health Care Fund 4,304,500 sh (New)
Pioneer Investments 1,704,700 sh (+15.56%)
Ken Fisher 143,251 sh (+7.63%)
Jean-Marie Eveillard 15,000 sh (unchged)
Prem Watsa 20,000 sh (unchged)
RS Investment Management Sold Out
Jim Simons Sold Out
Mariko Gordon Sold Out
Irving Kahn 1,541,870 sh (-1.32%)
» More
Q3 2013

HOLX Guru Trades in Q3 2013

Jim Simons 619,518 sh (New)
Manning & Napier Advisors, Inc 580,455 sh (New)
Paul Tudor Jones 250,000 sh (New)
Steven Cohen 1,021,427 sh (+37.22%)
Jean-Marie Eveillard 17,000 sh (+13.33%)
Irving Kahn 1,549,770 sh (+0.51%)
Prem Watsa 20,000 sh (unchged)
Louis Moore Bacon 300,000 sh (unchged)
Vanguard Health Care Fund 4,304,500 sh (unchged)
Ray Dalio Sold Out
Ken Fisher 143,200 sh (-0.04%)
Pioneer Investments 1,484,807 sh (-12.9%)
» More
Q4 2013

HOLX Guru Trades in Q4 2013

Joel Greenblatt 156,851 sh (New)
Carl Icahn 34,154,879 sh (New)
Vanguard Health Care Fund 7,379,300 sh (+71.43%)
Paul Tudor Jones 375,000 sh (+50%)
Jean-Marie Eveillard 17,000 sh (unchged)
Prem Watsa 20,000 sh (unchged)
Ken Fisher 143,200 sh (unchged)
Pioneer Investments Sold Out
Manning & Napier Advisors, Inc 564,735 sh (-2.71%)
Irving Kahn 1,349,570 sh (-12.92%)
Jim Simons 366,485 sh (-40.84%)
Steven Cohen 20,460 sh (-98%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Carl Icahn 2013-12-31 New Buy2.5%$20.51 - $22.899 $ 21.09-4%34154879
Vanguard Health Care Fund 2013-12-31 Add 71.43%0.21%$20.51 - $22.899 $ 21.09-4%7379300
Joel Greenblatt 2013-12-31 New Buy0.08%$20.51 - $22.899 $ 21.09-4%156851
Ray Dalio 2013-09-30 Sold Out 0.01%$18.69 - $23 $ 21.09-1%0
Vanguard Health Care Fund 2013-06-30 New Buy0.3%$19.04 - $22.82 $ 21.091%4304500
Mariko Gordon 2013-06-30 Sold Out 0.02%$19.04 - $22.82 $ 21.091%0
Ray Dalio 2013-06-30 New Buy0.01%$19.04 - $22.82 $ 21.091%43800
Joel Greenblatt 2012-09-30 Sold Out 0.09%$18.01 - $21.05 $ 21.098%0
George Soros 2012-09-30 Sold Out 0.05%$18.01 - $21.05 $ 21.098%0
Joel Greenblatt 2012-06-30 New Buy0.09%$16.38 - $22.06 $ 21.0914%69842
George Soros 2012-06-30 New Buy0.05%$16.38 - $22.06 $ 21.0914%200000
George Soros 2011-12-31 Sold Out 0.0032%$14.23 - $17.84 $ 21.0929%0
George Soros 2011-09-30 Reduce -34.74%$15.15 - $20.82 $ 21.0921%12400
George Soros 2011-06-30 New Buy0.01%$19.63 - $22.69 $ 21.090%19000
George Soros 2011-03-31 Sold Out $18.76 - $22.28 $ 21.094%0
Mario Gabelli 2011-03-31 Sold Out $18.76 - $22.28 $ 21.094%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Hologic Inc

Weekly CEO Buys Highlight: HOLX, EPB, CLMS, IDTI, BYI
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks
Edward Owens retired at the end of 2012, but his Vanguard Health Care Fund (VGHCX) lives on under the management of Jean M. Hynes CFA, a Vanguard senior vice president, partner and global industry analyst who joined the company in 2008. Owens outperformed every other U.S. mutual fund since its inception in 1984 through his retirement. Read more...

Ratios

vs
industry
vs
history
P/B 2.90
HOLX's P/B is ranked higher than
58% of the 277 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. HOLX: 2.90 )
HOLX' s 10-Year P/B Range
Min: 0.59   Max: 10.61
Current: 2.9

0.59
10.61
P/S 2.30
HOLX's P/S is ranked higher than
62% of the 293 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. HOLX: 2.30 )
HOLX' s 10-Year P/S Range
Min: 1.25   Max: 7.73
Current: 2.3

1.25
7.73
PFCF 14.50
HOLX's PFCF is ranked higher than
93% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.10 vs. HOLX: 14.50 )
HOLX' s 10-Year PFCF Range
Min: 6.51   Max: 2932
Current: 14.5

6.51
2932
EV-to-EBIT 125.00
HOLX's EV-to-EBIT is ranked lower than
68% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.63 vs. HOLX: 125.00 )
HOLX' s 10-Year EV-to-EBIT Range
Min: 12.7   Max: 177.3
Current: 125

12.7
177.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.00
HOLX's Price/DCF (Projected) is ranked higher than
88% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.43 vs. HOLX: 1.00 )
HOLX' s 10-Year Price/DCF (Projected) Range
Min: 0.41   Max: 12.14
Current: 1

0.41
12.14
Price/Median PS Value 0.90
HOLX's Price/Median PS Value is ranked higher than
76% of the 266 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. HOLX: 0.90 )
HOLX' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 2.9
Current: 0.9

0.17
2.9
Earnings Yield (Greenblatt) 0.80
HOLX's Earnings Yield (Greenblatt) is ranked lower than
62% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. HOLX: 0.80 )
HOLX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 7.9
Current: 0.8

0.6
7.9
Forward Rate of Return (Yacktman) 5.70
HOLX's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. HOLX: 5.70 )
HOLX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.4   Max: 76
Current: 5.7

-4.4
76

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HO1.Germany
Hologic Inc was incorporated in Massachusetts in October 1985 and reincorporated in Delaware in March 1990. The Company is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. The Company's core business segments are focused on breast health, diagnostics, GYN surgical and skeletal health. The Company's breast health products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), minimally invasive breast biopsy and tissue extraction devices, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products. It has also developed a new breast imaging platform, Dimensions, which utilizes a new technology, tomosynthesis, to produce 3D images. The Company's diagnostic product offerings include the ThinPrep System used mainly for cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test for pre-term birth risk assessment. The Company's surgical product offerings include the NovaSure System, and the Adiana System. The NovaSure System enables physicians to treat women suffering from excessive menstrual bleeding in a minimally invasive manner. The Adiana System is a form of permanent female contraception intended as an alternative to tubal ligation. It sells and services its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company's mammography and related products and subsystems compete on a worldwide basis with products offered by a number of competitors, including GE, Siemens, Philips, PlanMed, Agfa, Carestream Health, Fuji, IMS Giotto, Sectra and Toshiba. The manufacture, sale, lease and service of medical diagnostic and surgical devices and pharmaceutical products intended for commercial use are subject to extensive governmental regulation by the FDA in the United States and by a variety of regulatory agencies in other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide